Bristol-Myers Squibb Rating Reiterated by TheStreet (BMY)
Bristol-Myers Squibb (NYSE:BMY)‘s stock had its “buy” rating reiterated by investment analysts at TheStreet in a note issued to investors on Friday, Analyst Ratings News reports.
The analysts wrote, “Bristol-Myers Squibb Company (BMY) has been reiterated by TheStreet Ratings as a buy with a ratings score of B. The company’s strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
Several other analysts have also recently commented on the stock. Analysts at Jefferies Group reiterated a “hold” rating on shares of Bristol-Myers Squibb in a research note to investors on Friday, October 11th. Separately, analysts at Zacks upgraded shares of Bristol-Myers Squibb from an “underperform” rating to a “neutral” rating in a research note to investors on Wednesday, October 9th. They now have a $49.00 price target on the stock. Finally, analysts at Credit Suisse initiated coverage on shares of Bristol-Myers Squibb in a research note to investors on Tuesday, October 8th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Buy” and an average target price of $47.80.
Shares of Bristol-Myers Squibb (NYSE:BMY) traded down 0.44% on Friday, hitting $49.4499. The stock had a trading volume of 2,438,425 shares. Bristol-Myers Squibb has a 52-week low of $30.64 and a 52-week high of $49.78. The stock’s 50-day moving average is $45.45 and its 200-day moving average is $44.00. The company has a market cap of $81.411 billion and a price-to-earnings ratio of 60.65.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by $0.01. The company had revenue of $4.05 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the previous year, the company posted $0.48 earnings per share. The company’s revenue for the quarter was down 8.9% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb will post $1.73 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, November 1st. Stockholders of record on Friday, October 4th will be given a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a yield of 2.82%. The ex-dividend date of this dividend is Wednesday, October 2nd.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.